Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has been given an average recommendation of "Buy" by the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $22.00.
A number of analysts recently issued reports on the company. Citigroup reissued an "outperform" rating on shares of Aura Biosciences in a research report on Wednesday, March 26th. JMP Securities reissued a "market outperform" rating and issued a $19.00 price target on shares of Aura Biosciences in a research note on Friday, May 23rd. Finally, HC Wainwright upgraded shares of Aura Biosciences to a "buy" rating and set a $22.00 target price for the company in a research note on Wednesday, May 28th.
Check Out Our Latest Stock Report on AURA
Insider Buying and Selling
In related news, insider Conor Kilroy sold 7,162 shares of the company's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total transaction of $39,319.38. Following the completion of the transaction, the insider now directly owns 179,313 shares in the company, valued at $984,428.37. This represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Anthony S. Gibney purchased 50,000 shares of Aura Biosciences stock in a transaction on Friday, May 16th. The stock was bought at an average cost of $4.90 per share, with a total value of $245,000.00. Following the completion of the acquisition, the insider now owns 58,452 shares in the company, valued at approximately $286,414.80. This trade represents a 591.58% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 9,578 shares of company stock valued at $52,067. Company insiders own 5.40% of the company's stock.
Institutional Investors Weigh In On Aura Biosciences
Several hedge funds have recently made changes to their positions in AURA. BNP Paribas Financial Markets bought a new stake in Aura Biosciences in the 4th quarter valued at $50,000. GAMMA Investing LLC grew its position in Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock worth $57,000 after acquiring an additional 9,573 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Aura Biosciences in the 4th quarter valued at $87,000. Ascent Group LLC bought a new stake in shares of Aura Biosciences during the first quarter worth $124,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Aura Biosciences in the fourth quarter valued at $127,000. Institutional investors own 96.75% of the company's stock.
Aura Biosciences Stock Performance
Shares of AURA stock traded up $0.01 during trading on Friday, hitting $6.34. 13,030 shares of the company were exchanged, compared to its average volume of 232,309. The business's 50-day simple moving average is $5.64 and its 200 day simple moving average is $7.17. Aura Biosciences has a twelve month low of $4.34 and a twelve month high of $12.38. The firm has a market capitalization of $318.71 million, a price-to-earnings ratio of -3.66 and a beta of 0.43.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.08). On average, equities analysts forecast that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.
Aura Biosciences Company Profile
(
Get Free ReportAura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Stories
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
